Trial of Intravenous Immune Globulin in Dermatomyositis.
Rohit AggarwalChristina Charles-SchoemanJoachim SchesslZsuzsanna Bata-CsörgőMazen M DimachkieZoltan GrigerSergey MoiseevChester OddisElena SchiopuJiri VencovskýIrene BeckmannElisabeth ClodiOlga BugrovaKatalin DankóFloranne ErnsteNamita A GoyalMarvin HeuerMarie HudsonYessar M HussainChafic KaramNina MagnoloRonald NelsonNataliia PozurLiudmyla PrystupaMiklós SárdyGuillermo ValenzuelaAnneke J van der KooiTuan VuMargitta WormTodd Levinenull nullPublished in: The New England journal of medicine (2022)
In this 16-week trial involving adults with dermatomyositis, the percentage of patients with a response of at least minimal improvement based on a composite score of disease activity was significantly greater among those who received IVIG than among those who received placebo. IVIG was associated with adverse events, including thromboembolism. (Funded by Octapharma Pharmazeutika; ProDERM ClinicalTrials.gov number, NCT02728752.).
Keyphrases